Invention Grant
- Patent Title: Enhanced stem cell composition
-
Application No.: US16218314Application Date: 2018-12-12
-
Publication No.: US11052118B2Publication Date: 2021-07-06
- Inventor: Daniel Shoemaker , David Robbins , John D. Mendlein , Caroline Desponts
- Applicant: Fate Therapeutics, Inc.
- Applicant Address: US CA San Diego
- Assignee: Fate Therapeutics, Inc.
- Current Assignee: Fate Therapeutics, Inc.
- Current Assignee Address: US CA San Diego
- Agency: Greenberg Traurig, LLP
- Main IPC: A61K35/28
- IPC: A61K35/28 ; A61K35/51 ; C12N5/0789 ; A61K35/12

Abstract:
The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
Public/Granted literature
- US20190111085A1 ENHANCED STEM CELL COMPOSITION Public/Granted day:2019-04-18
Information query
IPC分类: